N/A N=200 Provision of HIV Self-Test Kit to Emergency Department Patients
HIV Infections
Primary: Number of Participants Who Did HIV Testing — 36; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=250 Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
Phase 4 N=212 Alignment of PrEP Use With HIV Risk in Young Women and Men
Pre-Exposure Prophylaxis · Sexually Transmitted Diseases, Bacterial · HIV Infections
Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits
N/A N=216 Crowdsourcing to Reduce HIV Stigma Among Adolescents and Young Adults in Kazakhstan
Stigma, Social · HIV Testing
Primary: Mean Score Change in Total HIV Stigma Scale — 47.48; 47.89; 44.60; 47.32 units on a scale — p=0.083
N/A N=500 Expanding HIV Testing Among Uganda Adults Who Utilize Traditional Healers
HIV/AIDS · Health Behaviors
Primary: Number of TH Clients Who Received HIV Testing — 57; 250 Participants — p=<0.001
Phase 4 N=30 An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal
HIV-2 Infection
Primary: Death — 0 Participants
N/A N=58 Texting to Improve Adherence in HIV+ With Bipolar Disorder
HIV Disease · Bipolar Disorder
Primary: Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) — 90.3; 90.0; 83.9; 90.0 percentage of taken doses — p=0.95
N/A N=189 The OPENS Trial: Offering Women PrEP (Aim 1)
Human Immunodeficiency Virus Transmission · Sexually Transmitted Diseases
Primary: PrEP Prescriptions (As Measured by Chart Review) — 1; 0 Participants — p=0.51
N/A N=151 Addressing Drug Use Stigma in Human Immunodeficiency Virus (HIV) Care and Treatment Clinics in Tanzania
Drug Use Stigma in HIV Treatment Clinics
Primary: Modified Opening Minds Scale for Health Providers (OMS-HC) — 22.92; 16.82 score on a scale
Phase 1 N=53 Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
HIV/AIDS
Primary: Adherence Rate — 20; 17 Participants — p=0.29
N/A N=12 Adaptation of the Friendship Bench Intervention for HIV-infected Perinatal Women in Lilongwe
Human Immunodeficiency Virus · Perinatal Depression
Primary: Intervention Feasibility- Number of Participants Enrolled in Each Arm — 5; 43; 44 Participants
N/A N=5 HIV Posterior Cheek Enlargement
HIV Posterior Cheek Enlargement
Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume
Phase 2 N=58 ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
HIV Infections
Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml
N/A N=1,181 Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Human Immunodeficiency Virus Infection · Sexually Transmitted Diseases
Primary: Self-reported Consistent Condom Use During Vaginal Intercourse in the Past 3 Months — 121; 103; 125; 93 Participants — p=.008
N/A N=151 Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
HIV Infection
Primary: Baseline HIV DNA Reservoir: Total HIV DNA — 3.83; 3.67; 3.40 Log10 HIV DNA copies/10^6 CD4 T cells — p=0.048